STセグメント上昇急性心筋梗塞 (ASSENT-4 PCI) の患者における,一次性対テネクテプラゼ促進経皮冠動脈介入:ランダム化試験
Lancet (London, England)
|February 21, 2006
まとめ
STセグメント上昇心筋梗塞 (STEMI) の経皮冠動脈介入 (PCI) 前にテネクテプラスを投与すると,死亡および脳卒中を含む主要な有害事象が増加しました. この便利化されたPCIアプローチは,標準PCI単独では推奨されません.
科学分野:
- 心臓病学 心臓病学
- 介入性心臓病学 介入性心臓病学
- 緊急医療 緊急医療
背景:
- 主要経皮冠動脈介入 (PCI) は,STセグメント上昇急性心筋梗塞 (STEMI) の好ましい治療法です.
- PCIの遅延は,患者のアウトカムに悪影響を及ぼす可能性があります.
- 遅延を軽減する戦略を調査することは,STEMIケアを改善するために不可欠です.
研究 の 目的:
- STEMI患者の遅れたPCIの前にフルドースのテネクテプラスを使用する有効性と安全性を評価する.
- この便利化されたPCI戦略が,標準PCIと比較して有害事象を減少させるかどうかを判断する.
主な方法:
- 1667人のSTEMI患者を対象としたランダム化対照試験で,PCIが1〜3時間の遅延を予想している.
- 患者は標準PCIまたはPCIのいずれかに割り当てられ,その前にフルドースのテネクテプラス,アスピリン,および分断されていないヘパリンが投与された.
- 主要エンドポイントは,90日以内の死亡,心不全,またはショックの複合体でした.
主要な成果:
- 容易なPCI群で病院での死亡率が高かったため,研究が早期に中止されました.
- 緩和されたPCIは,プライマリエンドポイント (19%対13%) の有意に高い割合と,脳卒中,再発 infarction,および再循環の割合の増加と関連していました.
- 主要な非脳性出血合併症において,グループ間の有意な差は認められなかった.
結論:
- STEMI患者におけるPCI前に全量テネクテプラスを使用する戦略は,主要な有害事象の増加と関連しています.
- この便利化されたPCIアプローチは推奨されませんし,標準PCIのみよりもリスクが高いです.
関連する概念動画
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...